Moderna, Inc. MRNA will launch earnings outcomes for its third quarter, earlier than the opening bell on Thursday, Nov. 7.
Analysts anticipate the Cambridge, Massachusetts-based firm to report a quarterly loss at $1.9 per share, versus a year-ago lack of $9.53 per share. Moderna tasks to report income of $1.25 billion for the quarter, in comparison with $1.83 billion a yr earlier, in accordance with knowledge from Benzinga Professional.
On Oct. 28, On Monday, Merck & Co Inc MRK and Moderna introduced the initiation of INTerpath-009, a pivotal Section 3 trial of V940 (mRNA-4157).
Moderna shares fell 2.8% to shut at $51.81 on Wednesday.
Benzinga readers can entry the most recent analyst rankings on the Analyst Inventory Scores web page. Readers can kind by inventory ticker, firm identify, analyst agency, ranking change or different variables.
Let’s take a look at how Benzinga’s most-accurate analysts have rated the corporate within the current interval.
- JP Morgan analyst Jessica Fye maintained an Underweight ranking and reduce the worth goal from $70 to $59 on Oct. 4. This analyst has an accuracy price of 61%.
- Jefferies analyst Michael Yee maintained a Maintain ranking and slashed the worth goal from $65 to $55 on Oct. 15. This analyst has an accuracy price of 63%.
- B of A Securities analyst Geoff Meacham maintained a Impartial ranking and reduce the worth goal from $130 to $110 on Sept. 13. This analyst has an accuracy price of 60%.
- Needham analyst Joseph Stringer reiterated a Maintain ranking on Sept. 13. This analyst has an accuracy price of 77%.
- Evercore ISI Group analyst Cory Kasimov maintained an In-Line ranking with a value goal of $120 on June 27. This analyst has an accuracy price of 70%.
Contemplating shopping for MRNA inventory? Right here’s what analysts assume:
Learn This Subsequent:
Market Information and Knowledge dropped at you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
